Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in Women
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the changes in urinary nerve growth factor (uNGF) levels after acute urinary tract infection (UTI) and to assess the role of uNGF in predicting UTI recurrence in women. Methods: Women with uncomplicated, symptomatic UTIs were enrolled. Cephalexin 500 mg (every 6 hours) was administered for 7–14 days to treat acute UTIs. Subsequently, the patients were randomized to receive either sulfamethoxazole/trimethoprim 800 mg/160 mg daily at bedtime, or celecoxib 200 mg daily for 3 months and were monitored for up to 12 months. NGF levels in the urine were determined at baseline, 1, 4, and 12 weeks after the initiation of prophylactic therapy, and were compared between women with first-time UTIs and recurrent UTIs, sulfamethoxazole/trimethoprim and celecoxib-treated women, and no UTI recurrence and UTI recurrence that occurred during the follow-up period. Twenty women free of UTIs served as controls. Results: A total of 139 women with UTI and 20 controls were enrolled in the study, which included 50 women with a firsttime UTI and 89 women with recurrent UTIs. Thirty-seven women completed the study. Women with recurrent UTIs (n=23) had a trend of lower uNGF levels than women with first-time UTIs (n=14). During follow-up, 9 women had UTI recurrence. The serial uNGF levels in women with UTI recurrence were significantly lower than those in women who did not have UTI recurrence during the follow-up period. Conclusions: The lower levels of uNGF in women with recurrent UTI and the incidence of UTI recurrence during follow-up suggest that lower uNGF might reflect the defective innate immunity in women with recurrent UTI.
Abstract
Purpose: To investigate the changes in urinary nerve growth factor (uNGF) levels after acute urinary tract infection (UTI) and to assess the role of uNGF in predicting UTI recurrence in women. Methods: Women with uncomplicated, symptomatic UTIs were enrolled. Cephalexin 500 mg (every 6 hours) was administered for 7–14 days to treat acute UTIs. Subsequently, the patients were randomized to receive either sulfamethoxazole/trimethoprim 800 mg/160 mg daily at bedtime, or celecoxib 200 mg daily for 3 months and were monitored for up to 12 months. NGF levels in the urine were determined at baseline, 1, 4, and 12 weeks after the initiation of prophylactic therapy, and were compared between women with first-time UTIs and recurrent UTIs, sulfamethoxazole/trimethoprim and celecoxib-treated women, and no UTI recurrence and UTI recurrence that occurred during the follow-up period. Twenty women free of UTIs served as controls. Results: A total of 139 women with UTI and 20 controls were enrolled in the study, which included 50 women with a firsttime UTI and 89 women with recurrent UTIs. Thirty-seven women completed the study. Women with recurrent UTIs (n=23) had a trend of lower uNGF levels than women with first-time UTIs (n=14). During follow-up, 9 women had UTI recurrence. The serial uNGF levels in women with UTI recurrence were significantly lower than those in women who did not have UTI recurrence during the follow-up period. Conclusions: The lower levels of uNGF in women with recurrent UTI and the incidence of UTI recurrence during follow-up suggest that lower uNGF might reflect the defective innate immunity in women with recurrent UTI.
참고문헌 (29)
- Franco AV, "Recurrent urinary tract infections", Best Pract Res Clin Obstet Gynaecol, 19, pp.861~873 (2005)
- Haylen BT, "An International Urogynecological Association (IUGA)", International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction, 2010, pp.29, 4~20
- Liu HT, "Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders", Formos Med Assoc, 109, pp.862~878 (2010)
- Chuang FC, "Overactive bladder changes with time: a 5-year longitudinal followup of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels", J Urol, 192, pp.458~463 (2014)
- Liu HT, "Urinary nerve growth factor in women with overactive bladder syndrome", BJU Int, 107, pp.799~803 (2011)
- Steers WD, "Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders", Nat Clin Pract Urol, 3, pp.101~110 (2006)
- Tuttle JB, "Neural input regulates tissue NGF and growth of the adult rat urinary bladder", J Auton Nerv Syst, 49, pp.147~158 (1994)
- Lowe EM, "Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis", Br J Urol, 79, pp.572~577 (1997)
- Liu HT, "Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment", Urology, 72, pp.104~108 (2008)
- Kim JC, "Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder", J Urol, 175, pp.1773~1776 (2006)
- Liu HT, "Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder", J Urol, 179, pp.2270~2274 (2008)
- Liu HT, "Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection", Eur Urol, 56, pp.700~706 (2009)
- Liu HT, "Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention", Neurourol Urodyn, 28, pp.78~81 (2009)
- Vizzard MA, "Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction", Exp Neurol, 161, pp.273~284 (2000)
- Yoshimura N, "Bladder afferent pathway and spinal cord injury:possible mechanisms inducing hyperreflexia of the urinary bladder", Prog Neurobiol, 57, pp.583~606 (1999)
- Shie JH, "Higher levels of cell apoptosis and abnormal Ecadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis", painful bladder syndrome, 2011, pp.108(2 Pt 2), E136~E141
- Cervero F, "Sensory innervation of the viscera: peripheral basis of visceral pain", Physiol Rev, 74, pp.95~138 (1994)
- Arya LA, "Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections", BJU Int, 110, pp.247~251 (2012)
- Chuang FC, "Increased urothelial cell apoptosis and chronic inflammation are associated with recurrent urinary tract infection in women", PLoS One, 8, pp.e63760~ (2013)
- Lichtenberger P, "Antimicrobial prophylaxis in women with recurrent urinary tract infections", Int J Antimicrob Agents, 38(Suppl), pp.36~41 (2011)
- Keller WR, "A review of anti-inflammatory agents for symptoms of schizophrenia", J Psychopharmacol, 27, pp.337~342 (2013)
- Hooton TM, "Diagnosis and treatment of uncomplicated urinary tract infection", Infect Dis Clin North Am, 11, pp.551~581 (1997)
- Hooton TM, "Recurrent urinary tract infection in women", Int J Antimicrob Agents, 17, pp.259~268 (2001)
- Foxman B, "Recurring urinary tract infection: incidence and risk factors", Am J Public Health, 80, pp.331~333 (1990)
- Krieger JN, "Urinary tract infections: what’s new?", J Urol, 168, pp.2351~2358 (2002)
- Stamm WE, "Management of urinary tract infections in adults", N Engl J Med, 329, pp.1328~1334 (1993)
- Svanborg C, "Bacterial virulence in urinary tract infection", Infect Dis Clin North Am, 11, pp.513~529 (1997)
- Mulvey MA, "Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses", Proc Natl Acad Sci U S A, 97, pp.8829~8835 (2000)
- Schilling JD, "Dynamic interactions between host and pathogen during acute urinary tract infections", Urology, 57(6 Suppl 1), pp.56~61 (2001)